国产精品又长又粗又爽又黄的毛片, 国产AV无码专区亚洲AV毛片搜, 丰满人妻被猛烈进入中文字幕四川, 国产精品一区二区三区国产女人喷,亚洲国产欧美日韩图片在线人,潘娇娇337p人艺体艺术,成人免费无码大片a毛片古装,一本到高清视频免费,人妻在线视频免费看

更新于 8月8日

醫(yī)藥銷售代表

6000-8000元

職位描述

醫(yī)藥企業(yè)處方藥直銷區(qū)域銷售腫瘤科華南大區(qū)醫(yī)藥批發(fā)/零售
??【百濟(jì)神州-縣域銷售精英招募令】??
?? *創(chuàng)新一哥百濟(jì)神州銷售崗位擴(kuò)招!?? 誠(chéng)邀推薦/自薦加入!
【公司】百濟(jì)神州 (BeiGene) - 立足中國(guó),創(chuàng)新全球的生物科技領(lǐng)導(dǎo)者
【崗位】 銷售代表 (正崗)
【工作地點(diǎn)】岳陽(yáng)下轄縣域醫(yī)院 (Base:平江縣)
【負(fù)責(zé)核心產(chǎn)品】
百澤安? (替雷利珠單抗)- 成功出海,最火PD-1抑制劑
百悅澤? (澤布替尼) - “國(guó)藥之光”,改寫NCCN指南的BTK抑制劑
百拓維? (戈舍瑞林微球) - 長(zhǎng)效緩釋新劑型
安加維? (地舒單抗注射液)
賽瑞替尼、曲美替尼、達(dá)拉非尼等前沿腫瘤治療藥物
【崗位要求】
1. 學(xué)歷專業(yè): 藥學(xué)相關(guān)專業(yè),??萍耙陨蠈W(xué)歷。
2. 能力素質(zhì): 積極主動(dòng),溝通表達(dá)能力強(qiáng),學(xué)習(xí)能力強(qiáng),責(zé)任心強(qiáng)。
3. 經(jīng)驗(yàn)要求: 有1-3銷售實(shí)習(xí)經(jīng)驗(yàn)者優(yōu)先,應(yīng)屆生需有醫(yī)藥企業(yè)實(shí)習(xí)經(jīng)驗(yàn)。
4. 其他要求: 能適應(yīng)縣域市場(chǎng)工作,帶車上崗者優(yōu)先。
【加入我們,你將】:
代表全球領(lǐng)先的創(chuàng)新腫瘤藥企,推廣重磅明星產(chǎn)品!
深耕極具潛力的縣域市場(chǎng),實(shí)現(xiàn)個(gè)人價(jià)值!
獲得行業(yè)領(lǐng)先的平臺(tái)資源與專業(yè)發(fā)展機(jī)會(huì)!
【立即行動(dòng)!】
?? 投遞簡(jiǎn)歷至: *******************
(郵件主題建議:姓名+應(yīng)聘岳陽(yáng)縣域銷售代表+Base平江)

工作地點(diǎn)

岳陽(yáng)市-平江縣-城關(guān)鎮(zhèn)北街431號(hào)

職位發(fā)布者

李陽(yáng)/人事經(jīng)理

昨日活躍
立即溝通
公司Logo百濟(jì)神州北京
About BeiGene BeiGene is a publically traded(BGNE, NASDAQ), globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. Our cancer biology platform addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models. We have a global team of over 200 individuals, including over 150 scientists and clinicians, and a world-renowned scientific advisory board, with deep scientific talent, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients around the world. Our clinical pipeline is comprised of novel oral small molecules and monoclonal antibodies(mAb) for cancer, including an anti-PD-1 monoclonal antibody, a best-in-class BTK inhibitor, a RAF dimer inhibitor, a best-in-class PARP inhibitor, and a variety of combination clinical studies. In addition, our robust preclinical programs are expected to generate more small molecule and mAb drugs for clinical development in coming years. For more information, please visit our website at www.beigene.com.
公司主頁(yè)